Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 10:6:100091.
doi: 10.1016/j.esmogo.2024.100091. eCollection 2024 Dec.

Prognostic markers in oesophageal and gastric cancer review. Are they ready for clinical practice?

V Kunene  1 , M Ding  1   2 , M Yap  2 , E A Griffiths  1   2 , P Taniere  1 , D Fackrell  1 , S Butler  3 , G Contino  2
Affiliations
Review

Prognostic markers in oesophageal and gastric cancer review. Are they ready for clinical practice?

V Kunene et al. ESMO Gastrointest Oncol. .

Abstract

Oesophageal and gastric cancer outcomes remain poor despite the introduction of new treatments in the past decade. Most patients subjected to chemotherapy or surgery do not, in the long term, benefit from treatment but suffer side-effects. Although next-generation sequencing has accelerated the identification of various genomic aberrations, most have yet to be applied to routine clinical practice. Here, we review published data from systemic reviews and meta-analyses from the past 8 years reporting prognostic markers and why these have not gained traction in clinical practice and how we can improve on this.

Keywords: adenocarcinoma; biomarkers; gastric cancer; genomic markers; oesophageal cancer; prognostic markers; squamous cell carcinoma immunohistochemistry; stomach cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow chart.
See this image and copyright information in PMC

References

    1. Chau I., Ashley S., Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol. 2009;27(19):e3–e4. - PubMed
    1. Fuchs C.S., Muro K., Tomasek J., et al. Prognostic factor analysis of overall survival in gastric cancer from two phase iii studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer. 2017;17(2):132–144. - PMC - PubMed
    1. American Cancer Society . 4th ed. American Cancer Society; Atlanta: 2018. Global Cancer Facts & Figures.
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed

LinkOut - more resources